NCT04844450View on ClinicalTrials.gov

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Fatty Liver Disease
Interventions
DRUG

JNJ-75220795

JNJ-75220795 will be administered subcutaneously.

DRUG

Placebo

Matching placebo will be administered subcutaneously.

Trial Locations (2)

33024

Research Centers of America, LLC, Hollywood

78240

Endeavor Clinical Trials, LLC, San Antonio

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY